menu
    • menu
    [{"orgOrder":0,"company":"Rigel Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ibafloxacin","moa":"IL-1-associated kinase 1 receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Rigel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rigel Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Rigel Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rigel Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ibafloxacin","moa":"IL-1-associated kinase 1 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rigel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Rigel Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Rigel Pharmaceuticals \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Ibafloxacin

    Menu

    Ibafloxacin

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Rigel Pharmaceuticals

                            U.S.A arrow
                            Plastics Recycling EU
                            Not Confirmed

                            Rigel Pharmaceuticals

                            U.S.A arrow
                            Plastics Recycling EU
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ibafloxacin

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Rigel Announces R289 Granted Fast Track Designation by the FDA for Lower-Risk MDS

                            Details : R289 is a prodrug of R835, an IRAK1/4 dual inhibitor, being investigated for the treatment of patients with previously-treated transfusion dependent lower-risk myelodysplastic syndrome (LR-MDS).

                            Product Name : R289-Prodrug

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            December 02, 2024

                            Lead Product(s) : Ibafloxacin

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Rigel Pharmaceuticals

                            U.S.A arrow
                            Plastics Recycling EU
                            Not Confirmed

                            Rigel Pharmaceuticals

                            U.S.A arrow
                            Plastics Recycling EU
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ibafloxacin

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Rigel to Present Four Posters Highlighting IRAK1/4 Inhibitor at the EULAR 2020 E-Congress

                            Details : Data related to R835, the company's investigational IRAK1/4 inhibitor, will be presented in two oral and two poster presentations at the European League Against Rheumatism (EULAR) 2020 E-Congress.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            March 06, 2020

                            Lead Product(s) : Ibafloxacin

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth